高级检索

精神分裂症研究进展

栗文靖, 许培扬, 纪志刚

栗文靖, 许培扬, 纪志刚. 精神分裂症研究进展[J]. 实用临床医药杂志, 2011, (5): 123-125. DOI: 10.3969/j.issn.1672-2353.2011.05.052
引用本文: 栗文靖, 许培扬, 纪志刚. 精神分裂症研究进展[J]. 实用临床医药杂志, 2011, (5): 123-125. DOI: 10.3969/j.issn.1672-2353.2011.05.052
shu

精神分裂症研究进展

  • 1.

    北京协和医学院,北京,100005;

  • 2.

    中国医学科学院医学信息研究所,北京,100020;

  • 3.

    北京协和医院泌尿外科,北京,100730

详细信息

  • 中图分类号: R749.3

摘要

    摘要
  • 摘要: 精神分裂症被命名于1908年4月24日.它由Bleuler医生在为德国精神病学协会所做的一次报告中正式提出,以替代之前的早老性痴呆.Bleule认为,该病既非一种痴呆,也并不具有"早老"的特质,因此他用希腊语schizein(分裂)和希腊语phren(灵魂、精神、心灵)的结合,来表达心理功能的断裂或分裂,而更准确的描述该病的症状[1].现代医学认为该病是一种症候群,为病因不明的一组症状和体征的集合.它主要是由观察到的精神病迹象定义的:如妄想、幻觉、认知和情感的障碍.通常情况下该病发于青春后期或成年早期[2].
    • HTML全文
    • 参考文献(50)
  • Kuhn R. Eugen Bleuler's concepts of psychopathology [J]. HISTORY OF PSYCHIATRY, 2004(3):361.doi: 10.1177/0957154X04044603.
    Insel T R. Rethinking schizophrenia [J]. Nature, 2010, (7321):187.doi: 10.1038/nature09552.
    Freedman R. Schizophrenia [J]. the New England Journal of Medicine, 2003, (18):1738.
    van Os J, S Kapur. Schizophrenia [J]. The Lancet, 2009, (9690):635.doi: 10.1016/S0140-6736(09)60995-8.
    Hegarty J D. One hundred years of schizophrenia:a metaanalysis of the outcome literature [J]. American Journal of Psychiatry, 1994, (10):1409.
    Ross C A. Neurobiology of schizophrenia [J]. Neuron, 2006(1):139.doi: 10.1016/j.neuron.2006.09.015.
    Allen A J. Endophenotypes in schizophrenia:a selective review [J]. Schizophrenia Research, 2009, (1-3):24.doi: 10.1016/j.schres.2009.01.016.
    Berridge K C, T E Robinson. Parsing reward [J]. Trends in Neurosciences, 2003(9):507.doi: 10.1016/S0166-2236(03)00233-9.
    Kirkpatrick B. A separate disease within the syndrome of schizophrenia [J]. Archives of General Psychiatry, 2001(2):165.doi: 10.1001/archpsyc.58.2.165.
    Niemi L T. Childhood developmental abnormalities in schizophrenia:evidence from high-risk studies [J]. Schizophrenia Research, 2003, (2-3):239.doi: 10.1016/S0920-9964(02)00234-7.
    Bentall R. Madness explained:why we must reject the Kraepelinian paradigm and replace it with a'complaint-orientated approach to understanding mental illness [J]. Medical Hypotheses, 2006(2):220.doi: 10.1016/j.mehy.2005.09.026.
    Cannon T D. The inheritance of intermediate phenotypes for schizophrenia [J]. Current Opinion in Psychiatry, 2005(2):135.doi: 10.1097/00001504-200503000-00005.
    Ettinger U. Antisaccade performance in monozygotic twins discordant for schizophrenia:the Maudsley twin study [J]. American Journal of Psychiatry, 2006(3):543.doi: 10.1176/appi.ajp.163.3.543.
    Hong L E. Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients [J]. Archives of General Psychiatry, 2006(3):259.doi: 10.1001/archpsyc.63.3.259.
    Erwin. P50 abnormalities in schizophrenia:relationship to clinical and neuropsychological indices of attention [J]. Schizophrenia Research, 1998(3):157.doi: 10.1016/S0920-9964(98)00075-9.
    Bramon E. Is there an association between the COMT gene and P300 endophenotypes [J]. European Psychiatry:the Journal of the Association of European Psychiatrists, 2006(1):70.
    Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia [J]. Nature, 2010, (7321):194.doi: 10.1038/nature09569.
    Ellison-Wright I. The anatomy of first-episode and chronic schizophrenia:an anatomical likelihood estimation meta analysis [J]. American Journal of Psychiatry, 2008(8):1015.doi: 10.1176/appi.ajp.2008.07101562.
    Boos H B. Brain volumes in relatives of patients with schizophrenia:a meta-analysis [J]. Archives of General Psychiatry, 2007(3):297.doi: 10.1001/archpsyc.64.3.297.
    Goldman A L. Heritability of brain morphology related to schizophrenia:a large-scale automated magnetic resonance imaging segmentation study [J]. Biological Psychiatry, 2008(5):475.doi: 10.1016/j.biopsych.2007.06.006.
    Lewis D A, Sweet R A. Schizophrenia from a neural circuitry perspective:advancing toward rational pharmacological therapies [J]. Journal of Clinical Investigation, 2009(4):706.doi: 10.1172/JCI37335.
    Hashimoto T. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia [J]. The Journal of Neuroscience, 2003, (15):6315.
    Selemon L D. The reduced neuropil hypothesis:a circuit based model of schizophrenia [J]. Biological Psychiatry, 1999(1):17.doi: 10.1016/S0006-3223(98)00281-9.
    Byne W. The thalamus and schizophrenia:current status of research [J]. Acta Neuropathologica, 2009(4):347.doi: 10.1007/s00401-008-0404-0.
    Uhlhaas P J. Abnormal neural oscillations and synchrony in schizophrenia [J]. Nature Reviews Neuroscience, 2010(2):100.doi: 10.1038/nrn2774.
    Kwon J S. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia [J]. Archives of General Psychiatry, 1999, (11):1001.doi: 10.1001/archpsyc.56.11.1001.
    KrishnanG P. Steady state visual evoked potential abnormalities in schizophrenia [J]. Clinical Neurophysiology, 2005(3):614.doi: 10.1016/j.clinph.2004.09.016.
    Roach B J. Event-related EEG time-frequency analysis:an overview of measures and an analysis of early gamma band phase locking in schizophrenia [J]. Schizophrenia Bulletin, 2008(5):907.doi: 10.1093/schbul/sbn093.
    Gallinat J. Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing [J]. Clinical Neurophysiology, 2004(8):1863.doi: 10.1016/j.clinph.2004.03.013.
    Cho R Y. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia [J]. Proceedings of the National Academy of Sciences of the United States of America, 2006, (52):19878.doi: 10.1073/pnas.0609440103.
    Uhlhaas P J. Neural synchrony in brain disorders:relevance for cognitive dysfunctions and pathophysiology [J]. Neuron, 2006(1):155.doi: 10.1016/j.neuron.2006.09.020.
    Aleman A. Strange feelings:do amygdala abnormalities dysregulate the emotional brain in schizophrenia [J]. Progress in Neurobiology, 2005(5):283.
    Achim A M. Episodic memory-related activation in schizophrenia:meta-analysis [J]. British Journal of Psychiatry, 2005, (DEC):500.doi: 10.1192/bjp.187.6.500.
    Brunet-Gouet E. Social brain dysfunctions in schizophrenia:a review of neuroimaging studies [J]. Psychiatry Research, 2006, (2-3):75.doi: 10.1016/j.pscychresns.2006.05.001.
    Walter H. Dysfunction of the social brain in schizophrenia is modulated by intention type:an fMRI study [J]. Social Cognitive and Affeetive Neuroscience, 2009(2):166.doi: 10.1093/scan/nsn047.
    Dierks T. Activation of Heschl' s gyrus during auditory hallucinations [J]. Neuron, 1999(3):615.doi: 10.1016/S0896-6273(00)80715-1.
    Hubl D. Pathways that make voices:white matter changes in auditory hallucinations [J]. Archives of General Psychiatry, 2004(7):658.doi: 10.1001/archpsyc.61.7.658.
    Guillin O. Neurobiology of dopamine in schizophrenia [J]. International Review of Neurobiology, 2007.1.doi: 10.1016/S0074-7742(06)78001-1.
    Fletcher P C. Perceiving is believing:a Bayesian approach to explaining the positive symptoms of schizophrenia [J]. Nature Reviews Neuroscience, 2009(1):48.doi: 10.1038/nrn2536.
    Schultz W. Multiple dopamine functions at different time courses [J]. Annual Review of Neuroscience, 2007():259.doi: 10.1146/annurev.neuro.28.061604.135722.
    Kapur S. How antipsychotics become anti-"psychotic"from dopamine to salience to psychosis [J]. Trends in Pharmacological Sciences, 2004(8):402.doi: 10.1016/j.tips.2004.06.005.
    Kapur S. Half a century of antipsychotics and still a central role for dopamine D2 receptors [J]. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003(7):1081.
    Leucht S. Second-generation versus first-generation antipsychotic drugs for schizophrenia:a meta-analysis [J]. The Lancet, 2009, (9657):31.doi: 10.1016/S0140-6736(08)61764-X.
    Agid O. Emerging drugs for schizophrenia [J]. Expert Opinion on Emerging Drugs, 2008(3):479.doi: 10.1517/14728214.13.3.479.
    Patel J K. Metabolic profiles of second-generation antipsychotics in early psychosis:findings from the CAFE study [J]. Schizophrenia Research, 2009, (1-3):9.doi: 10.1016/j.schres.2009.03.025.
    Buckley P F. Pharmacological treatment of negative symptoms of schizophrenia:therapeutic opportunity or cul-desac [J]. Acta Psychiatrica Scandinavica, 2007(2):93.doi: 10.1111/j.1600-0447.2007.00992.x.
    Thompson A. The DEBIT trial:an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards-a cluster randomized controlled trial [J]. Psychological Medicine, 2008(5):705.doi: 10.1017/S003329170700147X.
    Zygmunt A. Interventions to improve medication adherence in schizophrenia [J]. American Journal of Psychiatry, 2002, (10):1653.doi: 10.1176/appi.ajp.159.10.1653.
    Wright C. A systematic review of home treatment services-classification and sustainability [J]. Social Psychiatry and Psychiatric Epidemiology, 2004, (10):789.
    Burns T. Use of intensive case management to reduce time in hospital in people with severe mental illness:systematic review and meta-regression [J]. British Medical Journal, 2007, (7615):336.doi: 10.1136/bmj.39251.599259.55.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  134
  • HTML全文浏览量:  10
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 发布日期:  2011-08-01

目录

摘要
HTML全文
    参考文献(50)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    x 关闭 永久关闭